-
Uddannelse
Find uddannelse
Studievejledning
Kvalitet
- Forskning
-
Samarbejde
Virksomheder
Kommuner og regioner
Gymnasier
Myndigheder
-
Om AU
Organisation
Kontakt
Om AU
- Organisation
- Ledelse
- Strategi
- AU i tal
- AU's historie
- Internationalt samarbejde
- Bæredygtighed
- Campus 2.0
- Diversitet og ligestilling
- Ledige stillinger
- Presse
- Kontakt
Impaired Glucagon-Mediated Suppression of VLDL-triglyceride Secretion in Individuals with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review
DOI
- https://doi.org/10.2337/db22-0313
Forlagets udgivne version
- Institut for Klinisk Medicin - Hormon- og Knoglesygdomme
- Institut for Klinisk Medicin - SDCA-Steno Diabetes Center Aarhus
- Institut for Klinisk Medicin - Regionshospitalet Viborg
- Institut for Klinisk Medicin - MR Forskningscentret
- Institut for Klinisk Medicin - Lever-, Mave- og Tarmsygdomme
- Medicinsk Endokrinologisk Afd., MEA, NBG
Individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) have elevated plasma lipids as well as glucagon, although glucagon suppresses hepatic very low-density lipoprotein-triglyceride (VLDL-TG) secretion. We hypothesize that the sensitivity to glucagon in the hepatic lipid metabolism is impaired in MAFLD. We recruited 11 subjects with severe MAFLD (MAFLD+), 10 with mild MAFLD (MAFLD-), and seven overweight control subjects (CON). We performed a pancreatic clamp with a somatostatin analogue (Octreotide®) to suppress endogenous hormone production, combined with infusion of low-dose glucagon (0.65 ng/kg/min, t=0-270 min, LowGlucagon) followed by high-dose glucagon (1.5 ng/kg/min, t=270-450, HighGlucagon). VLDL-TG and glucose tracers were used to evaluate VLDL-TG-kinetics and endogenous glucose production (EGP). HighGlucagon suppressed VLDL-TG secretion compared to LowGlucagon. This suppression was markedly attenuated in MAFLD compared to CON (MAFLD+: 13% (SEM ±5%); MAFLD-: 10% (±3%); CON: 36% (±7%), P < 0.01), with no difference between MAFLD groups. VLDL-TG concentration and VLDL-TG oxidation rate increased during between LowGlucagon and HighGlucagon in MAFLD+ compared to CON. EGP transiently increased during HighGlucagon without any difference between the three groups. Individuals with MAFLD have a reduced sensitivity to glucagon in the hepatic triglyceride metabolism, which could contribute to the dyslipidemia seen in MAFLD patients. NCT04042142.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Diabetes |
| Vol/bind | 71 |
| Nummer | 11 |
| ISSN | 0012-1797 |
| DOI | |
| Status | Udgivet - nov. 2022 |
Bibliografisk note
© 2022 by the American Diabetes Association.
Se relationer på Aarhus Universitet Citationsformater
ID: 279831576